On June 20, 2016, the full Federal Circuit denied Mylan’s petitions for rehearing en banc in Acorda Therapeutics Inc. v. Mylan Pharms. Inc., 817 F.3d 755 (Fed. Cir. 2016), leaving intact the panel’s decision affirming two...more
6/23/2016
/ Abbreviated New Drug Application (ANDA) ,
BPCIA ,
Commercial Marketing ,
Corporate Counsel ,
Forum Selection ,
Generic Drugs ,
Manufacturers ,
Mylan Pharmaceuticals ,
Out-of-State Companies ,
Patent Litigation ,
Patent Validity ,
Patents ,
Personal Jurisdiction